Locations
Knoxville, TN, USA · Puerta de Hierro, Guadalajara Zapopan, Jalisco, Mexico
industry
Biotechnology
Size
1 - 10 employees
Stage
Other
founded in
2024
Narval develops next-generation antibody-like drugs using macrocyclic synthetic proteins that mimic the activity of antibodies and can be delivered through mucosal tissues for localized treatment and non-systemic delivery. Our Antibody Mimetic Proteins, or AMP for short, are developed by fusing CDR3 regions of a single domain shark antibodies to a conoprotein scaffold from a sea snail, and we optimize their capabilities using AI and ML algorithms. Narval’s AMPs offer a breakthrough solution for fast, accessible, and deployable therapeutics in areas like pandemics, emergency outbreaks, biodefense, animal health, and agricultural biosecurity.
Is this your company?
Something looks off?
